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Canakinumab for Childhood Sight-threatening Refractory
Uveitis: A Case Series
To the Editor:
Pediatric noninfectious uveitis embraces a group of inflammatory eye
diseases responsible for severe ocular complications and blindness.
Therapeutic options encompass topical or systemic steroid therapy, conven-
tional immune-modulatory therapy, and tumor necrosis factor-α (TNF-α)
antagonists1. The use of anti-TNF-α modifier immunosuppressant treatment
may apply to refractory cases2. Canakinumab is a human monoclonal
antibody (IgG1) directed against interleukin 1β. It has been successfully
used in cryopyrin-associated periodic syndromes3, systemic-onset juvenile
idiopathic arthritis (JIA)4, refractory Behçet disease5,6, and colchi-
cine-resistant familial Mediterranean fever7. Preliminary evidences suggest
the efficacy of canakinumab for refractory eye diseases in patients affected
by Blau syndrome8, juvenile Behçet syndrome9, and chronic infantile neuro-
logic cutaneous and articular syndrome10. Here we report 2 children affected
by refractory sight-threatening uveitis who have been successfully treated
with canakinumab.
Case 1. A 6-year-old boy was referred to our center for severe idiopathic
uveitis, presenting with bilateral cataract, vitreous inflammatory exudation,
and severe visual loss (right eye 20/32, left eye 20/50). The intraocular
pressure was within the normal limits. Clinical history and ocular findings
were consistent with the diagnosis of intermediate idiopathic uveitis.
On admission, intravenous steroid treatment was started (methylpred-
nisone 30 mg/kg/day for 3 days), followed by oral prednisone (1–2
mg/kg/day) and methotrexate (MTX; 10–15 mg/m2 weekly). Despite the
initial remission, during steroid tapering over 4 months, he developed vitreal
snow banks, vitreomacular traction, and retinal schisis, requiring surgical
treatment. We decided to discontinue MTX and introduce adalimumab
(ADA; 24 mg/m2 every 2 weeks). Throughout the followup, recurrent uveitis
flare with cystoid macular edema were documented; hence, after 18 months
of treatment, ADA was substituted with abatacept (ABA; 10 mg/kg every 4
weeks). This was used for a period of 7 months; nonetheless, ophthalmologic
examination highlighted persistence of ocular inflammation (vitreitis) and
macular edema (Figure 1A). Given the steroid dependence, the poor
response to previous therapies, and the high risk of visual loss, we suggested
the switch to canakinumab.
Case 2. A 9-year-old girl was referred to our hospital for recurrent uveitis
associated to JIA. At a different hospital, a previous therapeutic attempt with
MTX (15 mg/m2/week) and infliximab (5 mg/kg/dose) had soon been
discontinued because of allergic reaction to anti-TNF treatment.
Ophthalmologic evaluation highlighted keratic precipitate, Tyndall effect,
hypopyon, and visual loss (right eye 20/50, left eye 20/32). Given the
persistence of ocular inflammation and the recurrence of arthritis, we
decided to introduce ADA (24 mg/m2 every 2 weeks) associated to MTX
(15 mg/m2 weekly). This protocol ensured a stable clinical remission over
16 months. Thereafter, she flared again and recrudescence of ocular inflam-
mation along with arthritis reactivation were detected. Treatment with ABA
(10 mg/kg every 4 weeks) and MTX was started, leading to poor clinical
control and a new uveitis flare in the left eye with the development of
cataract and cystoid macular edema. Because of the recurrence of uveitis
and the persistence of arthritis, after an 8-week washout period, ABA was
switched to canakinumab.
Both children received intravenous methylprednisone (30 mg/kg for 3
days) followed by maintenance therapy with oral prednisone (0.25–1 mg/kg
daily) and canakinumab (2 mg/kg monthly). Patient 2 received concomitant
therapy with MTX, which was discontinued after 6 months from the intro-
duction of canakinumab. Ocular remission was achieved with vision
improvement, and oral steroid therapy was tapered after 2 months and
discontinued after 4 months in Patient 1 and 10 months in Patient 2. During
the 12-month period of followup, no new uveitis flares occurred. Visual
acuity normalized in both patients (right eye 20/25, left eye 20/20).
Intraocular pressure persisted within normal limits. Optical coherence
tomography excluded the recurrence of cystoid macular edema (Figure 1B).
The therapy has been well tolerated without major side effects, infusion
reactions, or drug-related adverse events. 
According to the other cases reported in the literature, our experience
suggests a potential involvement of canakinumab in maintaining remission
in children affected by severe sight-threatening uveitis refractory to previous
biological treatments. To our knowledge, ours is the first report of the use
of canakinumab for pediatric uveitis.
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Figure 1. Optical coherence tomography images at right eye show retinal morphology evolution (A) before and (B) after canakinumab.
A. Severe cystoid macula edema. B. Complete resolution in exudation along with mild derangement of the outer plexiform and
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in a patient with juvenile Behçet’s syndrome with refractory eye
disease. Ann Rheum Dis 2012;71:1589-91. 
 10.    Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H,
Nishikomori R, et al. Successful resolution of stromal keratitis and
uveitis using canakinumab in a patient with chronic infantile 
neurologic, cutaneous, and articular syndrome: a case study. 
J Ophthalmic Inflamm Infect 2015;5:34.
J Rheumatol 2016;43:7; doi:10.3899/jrheum.160064
1446 The Journal of Rheumatology 2016; 43:7
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2016. All rights reserved.
 Journal of Rheumatology
The on October 23, 2016 - Published by www.jrheum.orgDownloaded from 
